Protective effects of L-carnitine, N-acetylcysteine and genistein in an experimental model of liver fibrosis

Clinics and Research in Hepatology and Gastroenterology

Volumn 38, Issue 1, 2014, Pages 63-72

  Demiroren, Kaan ^a   Dogan, Yasar ^a   Kocamaz, Halil ^a   Ozercan, Ibrahim Hanifi ^a   Ilhan, Selcuk ^a   Ustundag, Bilal ^a   Bahcecioglu, Ibrahim Halil ^a  

^a YUZUNCU YIL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANIMALS; CARNITINE; DISEASE MODELS, ANIMAL; GENISTEIN; LIVER CIRRHOSIS; MALE; RATS; RATS, WISTAR;

EID: 84893933939     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2013.08.014     Document Type: Article

References (52)

1. Garcia-Tsao G., Friedman S., Iredale J., Pinzani M. Now there are many (stages) where before there was one: in search of a pathophysiological classification of cirrhosis. Hepatology 2010, 51:1445-1449.
2. Sohrabpour A.A., Mohamadnejad M., Malekzadeh R. Review article: the reversibility of cirrhosis. Aliment Pharmacol Ther 2012, 36:824-832.
3. Ramachandran P., Iredale J.P. Reversibility of liver fibrosis. Ann Hepatol 2009, 8:283-291.
4. Schiff E.R., Lee S.S., Chao Y.C., et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol 2011, 9:274-276.
5. Kweon Y.O., Goodman Z.D., Dienstag J.L., et al. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol 2001, 35:749-755.
6. Arif A., Levine R.A., Sanderson S.O., et al. Regression of fibrosis in chronic hepatitis C after therapy with interferon and ribavirin. Dig Dis Sci 2003, 48:1425-1430.
7. Camma C., Di Bona D., Schepis F., et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004, 39:333-342.
8. Wakim-Fleming J., Mullen K.D. Long-term management of alcoholic liver disease. Clin Liver Dis 2005, 9:135-149.
9. Hamaguchi E., Takamura T., Sakurai M., et al. Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis. Diabetes Care 2010, 33:284-286.
10. Czaja A.J., Carpenter H.A. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004, 40:646-652.
11. Hammel P., Couvelard A., O'Toole D., et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med 2001, 344:418-423.
12. Falize L., Guillygomarc'h A., Perrin M., et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology 2006, 44:472-477.
13. Muretto P., Angelucci E., Lucarelli G. Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation. Ann Intern Med 2002, 136:667-672.
14. Regimbeau J.M., Fuks D., Kohneh-Shahri N., Terris B., Soubrane O. Restrictive model of compensated carbon tetrachloride-induced cirrhosis in rats. World J Gastroenterol 2008, 14:6943-6947.
15. Manibusan M.K., Odin M., Eastmond D.A. Postulated carbon tetrachloride mode of action: a review. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2007, 25:185-209.
16. Weber L.W., Boll M., Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit Rev Toxicol 2003, 33:105-136.
17. Ozsoy S.Y., Ozsoy B., Ozyildiz Z., Aytekin I. Protective effect of L-carnitine on experimental lead toxicity in rats: a clinical, histopathological and immunohistochemical study. Biotech Histochem 2011, 86:436-443.
18. Ali S.A., Faddah L., Abdel-Baky A., Bayoumi A. Protective effect of L-carnitine and coenzyme Q10 on CCl4-induced liver injury in rats. Sci Pharm 2010, 78:881-896.
19. Annadurai T., Vigneshwari S., Thirukumaran R., Thomas P.A., Geraldine P. Acetyl-L-carnitine prevents carbon tetrachloride-induced oxidative stress in various tissues of Wistar rats. J Physiol Biochem 2011, 67:519-530.
20. Shaker M.E., Houssen M.E., Abo-Hashem E.M., Ibrahim T.M. Comparison of vitamin E, L-carnitine and melatonin in ameliorating carbon tetrachloride and diabetes induced hepatic oxidative stress. J Physiol Biochem 2009, 65:225-233.
21. Demirdag K., Bahcecioglu I.H., Ozercan I.H., Ozden M., Yilmaz S., Kalkan A. Role of L-carnitine in the prevention of acute liver damage induced by carbon tetrachloride in rats. J Gastroenterol Hepatol 2004, 19:333-338.
22. Rajasekar P., Viswanathan P., Anuradha C.V. Beneficial impact of L-carnitine in liver: a study in a rat model of syndrome X. Amino Acids 2008, 35:475-483.
23. Yapar K., Kart A., Karapehlivan M., et al. Hepatoprotective effect of L-carnitine against acute acetaminophen toxicity in mice. Exp Toxicol Pathol 2007, 59:121-128.
24. Ghanem H.M. Amelioration of Inducible Nitric Oxide Synthase, Insulin like growth factor-1 gene expression and insulin receptor substrate-1 in liver tissue of insulin resistant rats treated with L-Carnitine. Am J Biochem Biotech 2010, 6:195-203.
25. Xia Y., Li Q., Zhong W., Dong J., Wang Z., Wang C. L-Carnitine ameliorated fatty liver in high-calorie diet/STZ-induced type 2 diabetic mice by improving mitochondrial function. Diabetol Metab Syndr 2011, 15:3-31.
26. Pehlivan M., Coşkun A., Zengin A., Aslaner A., Yavuz T. Does L-carnitine increase serum TNF-α and IGF-1 during liver regeneration in the rat. Turk J Med Sci 2009, 39:875-880.
27. Galicia-Moreno M., Rodríguez-Rivera A., Reyes-Gordillo K., et al. N-acetylcysteine prevents carbon tetrachloride-induced liver cirrhosis: role of liver transforming growth factor-beta and oxidative stress. Eur J Gastroenterol Hepatol 2009, 21:908-914.
28. Pereira-Filho G., Ferreira C., Schwengber A., Marroni C., Zettler C., Marroni N. Role of N-acetylcysteine on fibrosis and oxidative stress in cirrhotic rats. Arq Gastroenterol 2008, 45:156-162.
29. Kuzu N., Metin K., Dagli A.F., et al. Protective role of genistein in acute liver damage induced by carbon tetrachloride. Mediators Inflamm 2007, 2007:36381.
30. Kulling S.E., Lehmann L., Metzler M. Oxidative metabolism and genotoxic potential of major isoflavone phytoestrogens. J Chromatogr B Analyt Technol Biomed Life Sci 2002, 777:211-218.
31. Polkowski K., Mazurek A.P. Biological properties of genistein. A review of in vitro and in vivo data. Acta Pol Pharm 2000, 57:135-155.
32. Aneja R., Upadhyaya G., Prakash S., Dass S.K., Chandra R. Ameliorating effect of phytoestrogens on CCl4-induced oxidative stress in the livers of male Wistar rats. Artif Cells Blood Substit Immobil Biotechnol 2005, 33:201-213.
33. Mohamed Salih S., Nallasamy P., Muniyandi P., Periyasami V., Carani Venkatraman A. Genistein improves liver function and attenuates non-alcoholic fatty liver disease in a rat model of insulin resistance. J Diabetes 2009, 1:278-287.
34. Paradkar P.N., Blum P.S., Berhow M.A., Baumann H., Kuo S.M. Dietary isoflavones suppress endotoxin-induced inflammatory reaction in liver and intestine. Cancer Lett 2004, 215:21-28.
35. Jiang L., Jiang L.S., Yan L.N., et al. Effects of epidermal growth factor receptor inhibitor genistein on proliferative cholangitis in rats. J Surg Res 2010, 162:59-67.
36. Eyer P., Podhradský D. Evaluation of the micromethod for determination of glutathione using enzymatic cycling and Ellman's reagent. Anal Biochem 1986, 153:57-66.
37. Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 2004, 37:277-285.
38. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005, 38:1103-1111.
39. Koca S.S., Bahcecioglu I.H., Poyrazoglu O.K., Ozercan I.H., Sahin K., Ustundag B. The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet. Inflammation 2008, 31:91-98.
40. Rivera C.A., Bradford B.U., Hunt K.J., et al. Attenuation of CCl4-induced hepatic fibrosis by GsCl3 treatment or dietary glycine. Am J Physiol Gastrointest Liver Physiol 2001, 281:200-207.
41. Bahcecioglu I.H., Koca S.S., Poyrazoglu O.K., et al. Hepatoprotective effect of infliximab, an anti-TNF-alpha agent, on carbon tetrachloride-induced hepatic fibrosis. Inflammation 2008, 31:215-221.
42. Maksimchik Y.Z., Lapshina E.A., Sudnikovich E.Y., Zabrodskaya S.V., Zavodnik I.B. Protective effects of N-acetyl-L-cysteine against acute carbon tetrachloride hepatotoxicity in rats. Cell Biochem Funct 2008, 26:11-18.
43. Boer L.A., Panatto J.P., Fagundes D.A., et al. Inhibition of mitochondrial respiratory chain in the brain of rats after hepatic failure induced by carbon tetrachloride is reversed by antioxidants. Brain Res Bull 2009, 80:75-78.
44. Ritter C., Reinke A., Andrades M., et al. Protective effect of N-acetylcysteine and deferoxamine on carbon tetrachloride-induced acute hepatic failure in rats. Crit Care Med 2004, 32:2079-2083.
45. Wong C.K., Ooi V.E., Wong C.K. Protective effects of N-acetylcysteine against carbon tetrachloride- and trichloroethylene-induced poisoning in rats. Environ Toxicol Pharmacol 2003, 14:109-116.
46. Hernandez-Gea V., Friedman S.L. Pathogenesis of liver fibrosis. Annu Rev Pathol 2011, 6:425-456.
47. Shepherd R.W., Ramm G.A. Fibrogenesis and cirrhosis. Pediatric gastrointestinal disease 2004, 80-88. BC Decker, Ontario. 4th ed. W.A. Walker, O. Goulet, R.E. Kleinman, P.M. Sherman, B.L. Shneider, I.R. Sanderson (Eds.).
48. Reeves H.L., Friedman S.L. Activation of hepatic stellate cells -a key issue in liver fibrosis. Front Biosci 2002, 7:808-826.
49. Kershenobich Stalnikowitz D., Weissbrod A.B. Liver fibrosis and inflammation. A review. Ann Hepatol 2003, 2:159-163.
50. Halliwell B. Free radicals, antioxidants, and human disease: curiosity, cause, or consequence?. Lancet 1994, 344:721-724.
51. Tarpey M.M., Wink D.A., Grisham M.B. Methods for detection of reactive metabolites of oxygen and nitrogen: in vitro and in vivo considerations. Am J Physiol Regul Integr Comp Physiol 2004, 286:431-444.
52. Mormone E., George J., Nieto N. Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches. Chem Biol Interact 2011, 193:225-231.